Immature granulocytes as a biomarker for diabetic retinopathy progression without anti-VEGF therapy: A cross sectional study

被引:0
作者
Bayram, Ergul [1 ]
Zor, Ramazan Kursad [2 ]
Ayan, Durmus [1 ,3 ]
机构
[1] Nigde Omer Halisdemir Univ, Res & Training Hosp, Med Biochem, Nigde, Turkiye
[2] Nigde Omer Halisdemir Univ, Fac Med, Ophthalmol, Nigde, Turkiye
[3] Nigde Omer Halisdemir Univ, Fac Med, Med Biochem, Nigde, Turkiye
关键词
Diabetic retinopathy; Immature granulocyte count; Immature granulocyte percentage; Inflammation; Delta neutrophil index; DELTA NEUTROPHIL INDEX; IMMUNE-INFLAMMATION INDEX; TO-LYMPHOCYTE RATIO; PROGNOSTIC MARKER; RESPONSE INDEX; COUNT; INFECTION;
D O I
10.1007/s13410-025-01484-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Diabetic retinopathy (DR) is one of the most common complications of diabetes and is the leading cause of low vision and blindness worldwide. Objective The present study aimed to evaluate delta neutrophil index (DNI), the immature granulocyte count (IG#), and percentage (IG%) in the diabetic group without retinopathy and in the diabetic group with DR. Methods A total of 175 participants were diagnosed with diabetes mellitus (DM (non-DR), 128 patients were diagnosed with nonproliferative diabetic retinopathy (NPDR) (n = 89), and one was diagnosed with diabetic proliferative retinopathy (PDR) (n = 39). Results The level of GR# and GR% in PDR was statistically significant than non-DR and NPDR (P = 0.03 and p = 0.02, respectively). The sensitivity and specificity of GR# and GR% for predicting progression from NPDR to PDR were determined to be 66.7% and 44.9%, respectively (area under curve [AUC] = 0.621, p = 0.029; 95% confidence interval [CI] = 0.512-0.730; and area under curve [AUC] = 0.623, p = 0.027, 95% confidence interval [CI] = 0.517-0.728). Additionally, IG# was not an independent risk factor for DR (p > 0.05). There were no significant differences in DNI among the NDR, NPDR, and PDR groups (p > 0.05). Conclusion IG# and IG% may be promising minimally invasive biomarkers for distinguishing NPDR from PDR but not DNI. We believe that they are markers that need to be confirmed in prospective studies for obtaining more reliable results in the detection of DR.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Therapeutic effects of anti-VEGF drugs, combined with laser therapy, on diabetic retinopathy and its effects on choroid thickness
    Wang, Ping
    Ma, Aihua
    Sun, Juanjuan
    Zhao, Bojun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (05): : 5969 - 5977
  • [32] Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population
    Pramanik, Subhasish
    Mondal, Lakshmi Kanta
    Paine, Suman Kalyan
    Jain, Sneha
    Chowdhury, Subhankar
    Ganguly, Upasana
    Ghosh, Sayantan
    Bose, Chiranjit
    Bhattacharjee, Koena
    Bhaduri, Gautam
    CLINICAL OPHTHALMOLOGY, 2021, 15 : 3341 - 3350
  • [33] Long-Term Impact of Diabetic Retinopathy on Response to Anti-VEGF Treatment in Neovascular AMD
    Boscia, Giacomo
    Bacherini, Daniela
    Vujosevic, Stela
    Grassi, Maria Oliva
    Borrelli, Enrico
    Giancipoli, Ermete
    Landini, Luca
    Pignataro, Mariagrazia
    Alessio, Giovanni
    Boscia, Francesco
    Viggiano, Pasquale
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (10)
  • [34] Early effects of intravitreal anti-VEGF agents on cornea and visual acuity in patients with diabetic retinopathy
    Liu, Xuanli
    Shen, Wei
    Xia, Wei
    Lu, Peirong
    CUTANEOUS AND OCULAR TOXICOLOGY, 2023, 42 (04) : 213 - 218
  • [35] Can immature granulocytes and neutrophil-lymphocyte ratio be biomarkers to evaluate diabetic nephropathy?: A cross-sectional study
    Yay, Fatih
    Bayram, Ergul
    Aggul, Hunkar
    Guclu, Ceren Onal
    Ayan, Durmus
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2024, 38 (09)
  • [36] Long term outcomes following anti-VEGF therapy for diabetic macular edema
    Maatouk, Christopher M.
    Sastry, Resya
    Singh, Rishi P.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2022, 17 (05) : 307 - 319
  • [37] Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy
    Sorour, Osama A.
    Sabrosa, Almyr S.
    Alibhai, A. Yasin
    Arya, Malvika
    Ishibazawa, Akihiro
    Witkin, Andre J.
    Baumal, Caroline R.
    Duker, Jay S.
    Waheed, Nadia K.
    INTERNATIONAL OPHTHALMOLOGY, 2019, 39 (10) : 2361 - 2371
  • [38] Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
    Uludag, Gunay
    Hassan, Muhammad
    Matsumiya, Wataru
    Pham, Brandon Huy
    Chea, Sophaktra
    Ngoc Trong Tuong Than
    Hien Luong Doan
    Akhavanrezayat, Amir
    Halim, Muhammad Sohail
    Do, Diana, V
    Quan Dong Nguyen
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (10) : 1275 - 1291
  • [39] Metformin therapy as a strategy to compensate anti-VEGF resistance in patients with diabetic macular edema
    Uwimana, Alexandre
    Ma, Cong
    Chen, Shengyao
    Ma, Xiang
    MEDICINE, 2022, 101 (42) : E31266
  • [40] Optical coherence tomography angiography in patients with diabetic retinopathy treated with anti-VEGF intravitreal injections: Case report
    Michalska-Malecka, Katarzyna
    Knudsen, Anna Heinke
    MEDICINE, 2017, 96 (45)